Comparison of cetuximab every 2 weeks versus standard once-weekly administration for the first-line treatment of RAS wild-type metastatic colorectal cancer among patients with left- and right-sided primary tumor location

被引：0
|
作者：
Kasper, S. [1 ]
Cheng, A-L. [2 ]
Rouyer, M. [3 ]
Foch, C. [4 ]
Lamy, F-X. [5 ]
Esser, R. [6 ]
Batech, M. [7 ]
Wong, C. M. J. [8 ]
Zhang, A. [9 ]
Brodowicz, T. [10 ]
Zielinski, C. [11 ,12 ]
机构：
[1] Univ Hosp Essen Westdeutsches Tumorzentrum, Med Oncol Dept, Essen, Germany
[2] Natl Taiwan Univ, Canc Ctr, Dept Internal Med & Oncol, Taipei, Taiwan
[3] Univ Bordeaux, Bordeaux PharmacoEpi, Bordeaux, France
[4] Merck KGaA, R&D Global Biostat Epidemiol & Med Writing, Darmstadt, Germany
[5] Merck KGaA, Global Epidemiol Dept, Darmstadt, Germany
[6] Merck KGaA, Global Med Affairs, Darmstadt, Germany
[7] Merck KGaA, Med Oncol, Darmstadt, Germany
[8] Cytel Singapore Pte Ltd, Project Based Serv, Singapore, Singapore
[9] Merck Serono, R&D Global Biostat, Beijing, Peoples R China
[10] Med Univ Vienna, Gen Hosp, Internal Med 1, Dept Med Oncol, Vienna, Austria
[11] Vienna Gen Hosp, Comprehens Canc Ctr, Oncol, Vienna, Austria
[12] Med Univ Vienna, Vienna, Austria
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.936
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
415P
引用
收藏
页码：S542 / S543
页数：2
相关论文
共 50 条
  • [31] Amphiregulin can predict treatment resistance to palliative first-line cetuximab plus FOLFIRI chemotherapy in patients with RAS wild-type metastatic colorectal cancer
    Kim, Sang-A
    Park, Hyejoo
    Kim, Kui-Jin
    Kim, Ji-Won
    Sung, Ji Hea
    Nam, Milang
    Lee, Ju Hyun
    Jung, Eun Hee
    Suh, Koung Jin
    Lee, Ji Yun
    Kim, Se Hyun
    Lee, Jeong-Ok
    Kim, Jin Won
    Kim, Yu Jung
    Kim, Jee Hyun
    Bang, Soo-Mee
    Lee, Jong Seok
    Lee, Keun-Wook
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [32] Amphiregulin can predict treatment resistance to palliative first-line cetuximab plus FOLFIRI chemotherapy in patients with RAS wild-type metastatic colorectal cancer
    Sang-A Kim
    Hyejoo Park
    Kui-Jin Kim
    Ji-Won Kim
    Ji Hea Sung
    Milang Nam
    Ju Hyun Lee
    Eun Hee Jung
    Koung Jin Suh
    Ji Yun Lee
    Se Hyun Kim
    Jeong-Ok Lee
    Jin Won Kim
    Yu Jung Kim
    Jee Hyun Kim
    Soo-Mee Bang
    Jong Seok Lee
    Keun-Wook Lee
    Scientific Reports, 11
  • [33] Phase II APEC trial: The impact of primary tumor side on outcomes of first-line cetuximab plus FOLFOX or FOLFIRI in patients with RAS wild-type metastatic colorectal cancer
    Price, Timothy
    Shen, Lin
    Ma, Brigette
    Esser, Regina
    Chen, Wenfeng
    Gibbs, Peter
    Lim, Robert
    Cheng, Ann-Lii
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 (04) : 225 - 230
  • [34] Association between early tumour shrinkage and outcomes in RAS-wild type patients with metastatic colorectal cancer receiving first-line FOLFOX or FOLFIRI plus cetuximab once every 2 weeks in the APEC study
    Cheng, A. L.
    Cornelio, G. H.
    Shen, L.
    Price, T. J.
    Yang, T. S.
    Chung, I. J.
    Dai, G.
    Lin, J. K.
    Sharma, A.
    Yeh, K. H.
    Ma, B.
    Zaatar, A.
    Guan, Z.
    Masood, N.
    Srimuninnimit, V.
    Yau, T. C.
    Beier, F.
    Chatterjee, S.
    Lim, R. S. C.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S367 - S367
  • [35] Emergence of RAS mutations in RAS wild type metastatic colorectal cancer patients receiving cetuximab as first-line treatment: A prospective study.
    Tsai, Hsiang-Lin
    Wang, Jaw-Yuan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 38 - 38
  • [36] Impact of primary tumor side on outcomes of every-2-weeks (q2w) cetuximab plus first-line FOLFOX or FOLFIRI in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 2 APEC trial.
    Price, Timothy Jay
    Shen, Lin
    Ma, Brigette
    Esser, Regina
    Chen, Wen-Feng
    Gibbs, Peter
    Lim, Robert S. C.
    Cheng, Ann-Lii
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [37] Biweekly cetuximab in combination with capecitabine and oxaliplatin (XELOX) or irinotecan (XELIRI) in the first-line and second-line treatment of patients with RAS wild-type metastatic colorectal cancer
    Zekri, Jamal
    Baghdadi, Mohammed Abbas
    Ibrahim, Refaei Belal
    Meliti, Abdelrazak
    Sobahy, Turki M.
    ECANCERMEDICALSCIENCE, 2022, 16 : 1 - 16
  • [38] Optimal molecular-targeted therapies as first-line treatment for RAS wild-type, right-sided metastatic colorectal cancer from the Analysis and Research in Cancers of the Digestive System (ARCAD) database
    Yamazaki, Kentaro
    Takeda, Yuriko
    Misumi, Toshihiro
    Suzuki, Motoko
    Wakabayashi, Masashi
    Bando, Hideaki
    Oki, Eiji
    Douillard, Jean-Yves
    Punt, Cornelis J. A.
    Van Cutsem, Eric
    Bokemeyer, Carsten
    Venook, Alan P.
    Maehara, Yoshihiko
    Heinemann, Volker
    Cremolini, Chiara
    Nakayama, Goro
    Andre, Thierry
    Shi, Qian
    De Gramont, Aimery
    Yoshino, Takayuki
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [39] Biweekly Cetuximab Plus FOLFOX6 as First-Line Therapy in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The CEBIFOX Trial
    Kasper, Stefan
    Meiler, Johannes
    Knipp, Heike
    Hohler, Thomas
    Reimer, Peter
    Steinmetz, Tilman
    Berger, Winfried
    Linden, Gabriele
    Reis, Henning
    Markus, Peter
    Paul, Andreas
    Dechene, Alexander
    Schumacher, Brigitte
    Kostbade, Karina
    Virchow, Isabel
    Ting, Saskia
    Worm, Karl
    Schmid, Kurt W.
    Herold, Thomas
    Wiesweg, Marcel
    Schuler, Martin
    Trarbach, Tanja
    CLINICAL COLORECTAL CANCER, 2020, 19 (04) : 236 - +
  • [40] Quality of life analysis in patients with RAS wild-type metastatic colorectal cancer treated with first-line FOLFIRI plus cetuximab in the CRYSTAL study
    Yamaguchi, K.
    Ando, M.
    Ooki, A.
    Beier, F.
    Guenther, S.
    Von Hohnhorst, P.
    Van Cutsem, E.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S370 - S371
12345